Efficacy is certainly one of the most interesting, and critical, aspects of a new vaccine idea:  does the vaccine work?  However, there are many other factors to consider in evaluating a vaccine opportunity for commercialization.  Safety, manufacturability / COG, regulatory considerations, intellectual property status, potential market, strategic fit, development status, compatibility with other vaccine components, availability of appropriate models / assays....these are among the pieces of information that are considered in evaluating (and valuing) a vaccine lead.  This talk will present one Industry perspective on the factors that might be considered in evaluating a vaccine opportunity for inclusion into a portfolio of vaccine projects.